Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02112734
Other study ID # HREC # 34168 A
Secondary ID
Status Active, not recruiting
Phase Phase 4
First received
Last updated
Start date December 2014
Est. completion date December 2028

Study information

Verified date November 2023
Source Murdoch Childrens Research Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

We report that Australia has the highest prevalence of Immunoglobulin(Ig)E-mediated food allergy in the world, with 10% of infants having challenge-proven food allergy in Melbourne. There has been a 5-fold increase in hospital admissions for life-threatening anaphylaxis. These changes are most pronounced in children less than 5 years, suggesting a causal role for early life determinants. We have primary data to inform hypotheses for the rise in food allergy, which appears to result from potentially modifiable factors related to the modern lifestyle, particularly Vitamin D insufficiency (VDI). We propose an intervention study to assess if infant Vitamin D supplementation during the first year of life significantly decreases the risk of early-onset food allergy and other allergic disease at 12 months (part 1) and 6 years of age (part 2). Australia is ideally placed to answer this important question since, unlike the USA, Canada and Europe, there are no population recommendations for routine infant supplementation with Vitamin D and we are one of the few developed countries that do not supplement the food chain supply with Vitamin D.


Description:

There is an urgent need to prevent the onset and progression of food allergy in our population. Evidence demonstrates that food allergy and atopic eczema represent the earliest manifestations of the atopic march with 50% of infants with food allergy predicted to develop respiratory allergic diseases later in life. We report that Australia has the highest prevalence of Immunoglobulin(Ig)E-mediated food allergy in the world, with 10% of infants having challenge-proven food allergy in Melbourne. There has been a 5-fold increase in hospital admissions for life-threatening anaphylaxis. These changes are most pronounced in children less than 5 years, suggesting a causal role for early life determinants. We have primary data to inform hypotheses for the rise in food allergy, which appears to result from potentially modifiable factors related to the modern lifestyle, particularly Vitamin D insufficiency (VDI), and have demonstrated an association between VDI and increased risk of challenge-proven food allergy in 12-month old infants, which supports numerous ecological studies showing an increased risk of food allergy the further a child resides from the equator (associated with decreased UV exposure and Vitamin D levels). Despite Australia's sunny climate, population rates of VDI have steadily increased in infants and pregnant women in parallel to the apparent rise in food allergic disease. This association is biologically plausible, as there is evidence Vitamin D is critical to the healthy development of the immune system in early life. We propose an intervention study to assess if infant Vitamin D supplementation during the first year of life significantly decreases the risk of early-onset food allergy and other allergic disease at 12 months (part 1) and 6 years of age (part 2). Australia is ideally placed to answer this important question since, unlike the USA, Canada and Europe, there are no population recommendations for routine infant supplementation with Vitamin D and we are one of the few developed countries that do not supplement the food chain supply with Vitamin D.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 2739
Est. completion date December 2028
Est. primary completion date April 2028
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 6 Weeks to 12 Weeks
Eligibility Inclusion Criteria: Each participant must meet the following criteria to be included in this study: - Healthy, term (born no earlier than 2 weeks before estimated date of delivery), predominantly breastfeeding infants aged 6 to 12 weeks (inclusive) who are expected to be predominantly breastfed for at least 6-months. This will be determined by answering yes/no to question 'do you intend/wish to breastfeed until your infant is at least 6 months of age.' Up to one bottle (approx. 120mL) of formula per 24 hours at the time of screening is acceptable, as this will contain <100 IU vitamin D. - Has a parent/legally acceptable representative (LAR) capable of understanding the informed consent document and providing consent on the subject's behalf, - The parent must expect to be able to complete 4 online questionnaires over the infant's first 12 months of life and for the infant to be available for skin prick testing (+/- food challenge) at The Royal Children's Hospital at 12 months of age. Exclusion Criteria: Participants meeting any of the following criteria will be excluded from the study: - Infants who are currently receiving vitamin D supplementation - Infants on medication that interferes with vitamin D metabolism - Poor health due to a current or past significant disease state or congenital abnormality. - Prematurity <37 weeks/low birth weight <2500 g/Small for gestational age (SGA) - Unable to provide consent without the aid of an interpreter. - Women at high risk of vitamin D deficiency with infants on vitamin D supplementation.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Vitamin D
400 IU/daily until age 12 months
placebo
identical placebo daily

Locations

Country Name City State
Australia Murdoch Childrens Research Institute Melbourne Victoria

Sponsors (1)

Lead Sponsor Collaborator
Murdoch Childrens Research Institute

Country where clinical trial is conducted

Australia, 

References & Publications (2)

Allen KJ, Koplin JJ, Ponsonby AL, Gurrin LC, Wake M, Vuillermin P, Martin P, Matheson M, Lowe A, Robinson M, Tey D, Osborne NJ, Dang T, Tina Tan HT, Thiele L, Anderson D, Czech H, Sanjeevan J, Zurzolo G, Dwyer T, Tang ML, Hill D, Dharmage SC. Vitamin D insufficiency is associated with challenge-proven food allergy in infants. J Allergy Clin Immunol. 2013 Apr;131(4):1109-16, 1116.e1-6. doi: 10.1016/j.jaci.2013.01.017. Epub 2013 Feb 27. — View Citation

Allen KJ, Panjari M, Koplin JJ, Ponsonby AL, Vuillermin P, Gurrin LC, Greaves R, Carvalho N, Dalziel K, Tang ML, Lee KJ, Wake M, Curtis N, Dharmage SC. VITALITY trial: protocol for a randomised controlled trial to establish the role of postnatal vitamin D supplementation in infant immune health. BMJ Open. 2015 Dec 16;5(12):e009377. doi: 10.1136/bmjopen-2015-009377. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The prevalence of challenge-proven food allergy at 12 months of age The prevalence of challenge-proven food allergy at 12 months of age determined by a positive SPT and a positive oral food challenge At 12 months of age
Primary The occurrence of definite food allergy or tolerance at 6 years of age The occurrence of definite food allergy or tolerance at 6 years of age can only be determined by combining data from an oral food challenge, a skin prick test (SPT) and/or serum specific IgE test, and/or parent/self-reported ingestion history and reactions to the index food. At 6 years of age
Secondary The prevalence of food sensitisation at 12 months of age determined by SPT positive The prevalence of food sensitisation at 12 months of age determined by SPT positive At 12 months of age
Secondary The prevalence of doctor diagnosed eczema during the first postnatal year The prevalence of doctor diagnosed eczema during the first postnatal year During the first postnatal year
Secondary The prevalence of vitamin D insufficiency (serum concentration of 25(OH)D <50 nmol/L ) at age 12 months determined by measuring blood taken at the 12 month clinic visit The prevalence of vitamin D insufficiency (serum concentration of 25(OH)D <50 nmol/L ) at age 12 months determined by measuring blood taken at the 12 month clinic visit At 12 months of age
Secondary Allergy-related healthcare utilisation within the first 12 months of life Allergy-related healthcare utilisation within the first 12 months of life Within the first 12 months of life
Secondary Infection episodes within the first 12 months of life Infection episodes within the first 12 months of life Within the first 12 months of life
Secondary Measure of height at 12 months of age Measure of height at 12 months of age At 12 months of age
Secondary Measure of weight at 12months of age Measure of weight at 12months of age At 12 months of age
Secondary Wheeze episodes within the first 12 months of life Wheeze episodes within the first 12 months of life Within the first 12 months of life
Secondary The occurrence of food sensitisation at 6 years of age determined by SPT positive The occurrence of food sensitisation at 6 years of age determined by SPT positive At 6 years of age
Secondary The occurrence of asthma in the first 6 years of life The occurrence of asthma at 6 years of age At 6 years of age
Secondary The occurrence of eczema in the first 6 years of life The occurrence of eczema in the first 6 years of life Within first 6 years of life
Secondary The prevalence of vitamin D insufficiency (serum concentration of 25(OH)D <50 nmol/L ) at age 6 years determined by measuring blood taken at the 6 year clinic visit The prevalence of vitamin D insufficiency (serum concentration of 25(OH)D <50 nmol/L ) at age 6 years determined by measuring blood taken at the 6 year clinic visit At 6 years of age
Secondary Allergy-related healthcare utilisation in the first 6 years of life Allergy-related healthcare utilisation in the first 6 years of life by data linkage from MBS and PBS Within first 6 years of life
Secondary Measure of height at 6 years of age Measure of height at 6 years of age At 6 years of age
Secondary Measure of Waist circumference at 6 years of age Measure of Waist circumference at 6 years of age At 6 years of age
Secondary Measure of Hip circumference at 6 years of age Measure of Hip circumference at 6 years of age At 6 years of age
Secondary Lung function at 6 years of age Lung function: bronchial responsiveness is measured using the percent change from baseline and absolute changes in forced expiratory volume (FEV) in 1 second and/or forced vital capacity (FVC) at 6 years of age At 6 years of age
Secondary The occurrence of rhinitis in the first 6 years of life The occurrence of rhinitis in the first 6 years of life Within first 6 years of life
Secondary Psychosocial Distress at 6 years of age Psychosocial health at 6 years of age by Kessler Psychological Distress Scale-10 (K-10) for parents The K10 scale involves 10 questions about emotional states each with a five-level response scale. Each item is scored from one 'none of the time' to five 'all of the time'. Scores of the 10 items are then summed, yielding a minimum score of 10 and a maximum score of 50. Low scores indicate low levels of psychological distress and high scores indicate high levels of psychological distress. At 6 years of age
Secondary Psychosocial health at 6 years of age Psychosocial health at 6 years of age by Strengths and Difficulties Questionnaire (SDQ) for child
SDQ ask about 25 attributes, some positive and others negative.bThese 25 items are divided between 5 scales:
emotional symptoms (5 items) } 1) to 4) added together to generate a total difficulties score (based on 20 items)
conduct problems (5 items)
hyperactivity/inattention (5 items)
peer relationship problems (5 items)
prosocial behaviour (5 items)
At 6 years of age
Secondary Quality of life at 6 years of age Quality of life (QL) at 6 years of age by Child Health Utility 9D (CHU9D, parent proxy version; PedsQL Parent Report for Young Children ages 5-7) The questionnaire has 9 questions with 5 response levels per question. The CHU9D allows the analyst to obtain quality adjusted life years (QALYs) directly for use in cost utility analysis. At 6 years of age
Secondary Quality of life regarding Food Allergy at 6 years of age Quality of life (QL) at 6 years of age by Food Allergy Quality of Life Questionnaires-Parent Form (FAQLQ-PF) All items are scored on a 7-point Likert scale from 0 (not at all troubled) to 6 (extremely troubled) [22]. The total scores are divided by the number of items answered, giving a range of scores from 0 to 6, with higher values indicating a poorer quality of life At 6 years of age
Secondary Cardiovascular health (vascular function) at 6 years of age Cardiovascular health at 6 years of age determined by assessing vascular function through a pulse doppler recording of the blood flow At 6 years of age
Secondary Cardiovascular health (Carotid and aortic Intima-Media Thickness) at 6 years of age Cardiovascular health (Carotid and aortic Intima-Media Thickness) at 6 years of age by acquiring images with simultaneous ECG gating At 6 years of age
Secondary Cardiovascular health (Blood pressure) at 6 years of age Cardiovascular health (Brachial and central blood pressure ) at 6 years of age will be measured using the SphygmoCor® XCEL system. At 6 years of age
Secondary Cardiovascular health (Arterial stiffness) at 6 years of age Cardiovascular health (Arterial stiffness ) at 6 years of age will be assessed by central and peripheral pulse wave velocity (PWV) and pressure waveform analysis (PWA) using a cuff for the femoral artery and tonometer pressure sensor for the carotid artery. At 6 years of age
Secondary Dental health at 6 years of age Dental health at 6 years of age: A registered oral health professional will examine the participant's mouth and teeth, checking for cavities/dental decay as well as developmental mark on the teeth. In addition, a 3D scan and/or photographs of the participant's teeth will be taken to document findings. At 6 years of age
Secondary Hearing health at 6 years of age Hearing health at 6 years of age by using SHOEBOX® Audiometry Professional Edition to measure hearing threshold At 6 years of age
See also
  Status Clinical Trial Phase
Withdrawn NCT03089476 - Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy N/A
Recruiting NCT05839405 - Food Allergy in the Brain
Completed NCT02552537 - iFAAM: The Impact of Proton-pump Inhibitors (Antacids) on Threshold Dose Distributions Phase 4
Completed NCT01634737 - Crustacean Allergy and Dust Mites Sensitization N/A
Recruiting NCT05521711 - TRADE Trial - Tree Nut Immunotherapy Route Development and Evaluation N/A
Completed NCT05072665 - Fast Allergy Sensitivity Test N/A
Active, not recruiting NCT04887441 - Allergology: Information, Data and Knowledge Organization
Recruiting NCT03265262 - The Basophil Activation Test as a Diagnostic Tool in Pediatric Food Allergy N/A
Completed NCT04186949 - Early Origins of Allergy and Asthma
Completed NCT02490007 - Pertussis Immunisation and Food Allergy
Recruiting NCT03151252 - Improvement of Foodallergy Diagnostic in Gastrointestinal Tract N/A
Completed NCT02159833 - Intranasal Diagnostics in Food Allergy: a Feasibility Study N/A
Completed NCT02354729 - Encouraging Allergic Young Adults to Carry Epinephrine N/A
Completed NCT02377284 - Prevention and Management of Food Allergies N/A
Completed NCT02640560 - One-year Survey of Anaphylaxis in Outpatient Children Allergic to Peanuts, Walnuts/Hazelnuts, Shellfish N/A
Enrolling by invitation NCT06097572 - Improved Diagnostics in Food Allergy Study N/A
Recruiting NCT04606615 - Skin Barrier Abnormalities and Oxidative Stress Response
Recruiting NCT05785299 - Clinical Versus Home Introduction of Milk in Children With Non-IgE-mediated Cow's Milk Allergy N/A
Not yet recruiting NCT06112873 - Quality of Life in Food Allergy: Validation of Three Mini-questionnaires
Completed NCT03337802 - Effect of Mediterranean Diet During Pregnancy on the Onset of Overweight and Obesity in the Offspring N/A